이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

REstoration of Communication and LAnguage With Intracortical Microelectrodes (RECLAIM)

2026년 11월 5일 업데이트: Nitin Tandon, The University of Texas Health Science Center, Houston

Early Feasibility Study of the Restoration of Communication and Language With Intracortical Microelectrodes (RECLAIM) System

The purpose of this study is to investigate the safety and feasibility of using distributed intracortical recordings from the language network to decode intended language output in individuals with severe communication impairment due to severe communication impairment resulting from amyotrophic lateral sclerosis (ALS), locked-in syndrome, and brain injury including from stroke.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

4

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

    • Texas
      • Houston, Texas, 미국, 77030
        • The University of Texas Health Science Center at Houston
        • 수석 연구원:
          • Nitin Tandon, MD
        • 연락하다:
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

22년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Clinical diagnosis of ALS, locked-in syndrome, or stroke

    1. ALS - ALS patients who in the opinion of the treating neurologist have at least 3 years of survival
    2. Locked-in Syndrome as a result of brain-stem stroke or traumatic brain-stem injury - patients who in the opinion of the treating neurologist have at least 3 years of survival
    3. Stroke (either ischemic or hemorrhagic) - for patients with prior stroke, the original cause of the stroke (e.g., arteriovenous malformation, carotid stenosis, atrial fibrillation, heart disease, hypertension) must have been addressed and the patient must not have had a recurrent stroke at least within the prior 12 months
  • ALS diagnosis, stroke, or Locked-in syndrome (LIS) etiology onset occurred at least one year prior to enrollment

  • Minimal communication ability as assessed by a speech-language pathologist

    1. unable to produce more than 10 total unique intelligible words when reading the Rainbow Passage and Grandfather Passage, and
    2. unable to write or type more than 10 unique words from a dictated list of 20 words.
  • Limited upper limb strength based on the Medical Research Council Scale for Muscle Strength

    1. ≤3/5 strength throughout both arms for those with non-progressive conditions (stroke or traumatic brain-stem injury)
    2. ≤4/5 strength throughout both arms for those with ALS

    i. For patients with 4/5 strength, they must have a documented decline in speech or upper extremity function in the preceding 12 months.

  • Has a means of communication sufficient to enable understanding of research protocol and provide consent (e.g. eye blinks or eye movements, use of assistive technology). Thus patients are severely impaired with regards to naturalistic communication, but able to make decisions regarding their own care

  • Ability to understand and comply with study session instructions

  • Must live within a 90-minute drive of study site and willing to travel to study site up to three days per week for duration of the study

  • Has a stable psychosocial support system with caregiver capable of providing care during post-operative periods and monitoring participant throughout the study

  • Stable ventilator status - ventilator requirements have not changed over prior 6 months and ventilator status does not impose additional substantial risks to subject participation, including travel to the investigation site

Exclusion Criteria:

  • Psychiatric conditions including current diagnosis of major psychiatric illness, significant cognitive impairment (based on a neuropsychological assessment by a clinical psychologist), suicidal ideation with intent/plan. [Columbia-Suicide Severity Rating Scale (C-SSRS) Categories 4-5)] or suicidal behavior within 12 months, or substance abuse/narcotic/alcohol dependence within 12 months.
  • Neurological disorders including current diagnosis of epilepsy, abnormal pre-surgical neuroimaging precluding safe implant placement (per neurosurgical team), prior ipsilateral craniotomy, or hydrocephalus with or without ventricular shunt.
  • Implanted electronic devices including pacemakers, cardiac defibrillators, spinal cord stimulators, vagal nerve stimulators, deep brain stimulators, or cochlear implants.
  • Cardiovascular disorders including acute myocardial infarction (MI) or cardiac arrest within 6 months, significant cardiovascular impairment contraindicating surgery.
  • Hematological disorders requiring chronic anticoagulation and medical contraindication to discontinuing anticoagulant medications perioperatively.
  • Dermatological conditions causing excessive skin sloughing, poor wound healing, existing scalp lesions, or skin breakdown.
  • Infectious/immunological conditions including active infections, unexplained fever, HIV infection, ongoing chronic infections, medical conditions predisposing to high infection risk, chronic steroid or immunosuppressive therapy, or active cancer within 1 year requiring chemotherapy.
  • Medical contraindications including conditions contraindicating chronically implanted devices (osteomyelitis, diabetes, hepatic failure, autoimmune disease/disorders with associated altered immune responses) or other chronic unstable medical conditions interfering with participation.
  • Surgical contraindications including medical contraindications to general anesthesia, craniotomy, or surgery; significant pulmonary, metabolic, or renal impairments making surgical procedure unsafe.
  • Other exclusions including pregnancy (confirmed by blood test), nursing, inadequate contraception, correction vision worse than 20/100, limited English proficiency, or concurrent participation in device/drug trials.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 다른
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: RECLAIM System

6 microelectrode grids will be implanted within the dominant hemisphere, placed across key speech and language cortical regions. The device will be kept implanted for up to 5 years and study sessions will be conducted 3-5 times per week

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
기간
Safety as assessed by the number and type of adverse events that occur
기간: From time of implant to one year post-implant
From time of implant to one year post-implant

2차 결과 측정

결과 측정
측정값 설명
기간
Safety as assessed by the number of participants with device explanted
기간: From time of implant to one year post-implant
From time of implant to one year post-implant
Safety as assessed by the number of participants with Serious Adverse Events that result in death or permanently increased disability
기간: From time of implant to one year post-implant
From time of implant to one year post-implant
Effectiveness of the device as assessed by the Word error rate (WER)
기간: Every three months for the first two years post-implant
Every three months for the first two years post-implant
Effectiveness of device as assessed by the Phoneme error rate (PER)
기간: Every three months for the first two years post-implant
Every three months for the first two years post-implant
Effectiveness of the device as assessed by the Bilingual Evaluation Understudy (BLEU) Score
기간: Every three months for the first two years post-implant

BLEU (Bilingual Evaluation Understudy) quantifies, on a range of 0-1, the overlap between the decoded text and the reference text based on matching n-grams. Higher BLEU scores indicate that the decoded output more closely matches the reference at the level of local word sequences.

Every three months for the first two years post-implant
Effectiveness of the device as assessed by the Bidirectional Encoder Representations from Transformers (BERT) Score
기간: Every three months for the first two years post-implant

BERT Score compares the semantic similarity (on a range of -1 to 1) between the decoded text sequence and the reference text using a pretrained language model (BERT). Higher scores indicated stronger semantic alignment.

Every three months for the first two years post-implant

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 11월 1일

기본 완료 (추정된)

2035년 1월 1일

연구 완료 (추정된)

2039년 4월 1일

연구 등록 날짜

최초 제출

2026년 10월 29일

QC 기준을 충족하는 최초 제출

2026년 11월 5일

처음 게시됨 (실제)

2026년 11월 12일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 12일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 5일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • HSC-MS-26-0020

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

예

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .